|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/473 | (2006.01) |
| A61P 25/00 | (2006.01) | ||
| A61P 25/14 | (2006.01) | ||
| A61P 43/00 | (2006.01) |
| (11) | Number of the document | 3936130 |
| (13) | Kind of document | T |
| (96) | European patent application number | 21178882.3 |
| Date of filing the European patent application | 2015-05-06 | |
| (97) | Date of publication of the European application | 2022-01-12 |
| (45) | Date of publication and mention of the grant of the patent | 2024-02-14 |
| (46) | Date of publication of the claims translation | 2024-04-25 |
| (30) | Number | Date | Country code |
| 201461989240 P | 2014-05-06 | US |
| (72) |
O'BRIEN, Christopher , US
|
| (73) |
Neurocrine Biosciences, Inc. ,
12780 El Camino Real, San Diego, California 92130,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Valbenazino dozavimo schema, skirta hiperkinetinio judrumo sutrikimų gydymui |
| VALBENAZINE DOSAGE REGIMEN FOR THE TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS |
| Payment date | Validity (years) | Amount | |
| 2025-04-22 | 11 | 289.00 EUR |
| 2026-05-06 |